Thrombin Inhibitor Screening Assay Kit (Fluorometric) (ab197007) is an assay where the synthetic AMC-based peptide substrate provided is proteolytically cleaved by Thrombin in order to release a fluorophore, AMC, which can be easily quantified by fluorescence reader at Ex/Em = 350/450 nm.
Select an associated product type
Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing. Activates coagulation factor XI (F11); activation is promoted by the contact with negatively charged surfaces (PubMed:2019570, PubMed:21976677). Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2 and IL8/CXCL8, in endothelial cells (PubMed:30568593, PubMed:9780208).
Prothrombin, Coagulation factor II, F2
Thrombin Inhibitor Screening Assay Kit (Fluorometric) (ab197007) is an assay where the synthetic AMC-based peptide substrate provided is proteolytically cleaved by Thrombin in order to release a fluorophore, AMC, which can be easily quantified by fluorescence reader at Ex/Em = 350/450 nm.
Thrombin Inhibitor Screening Assay Kit (Fluorometric) (ab197007) is an assay where the synthetic AMC-based peptide substrate provided is proteolytically cleaved by Thrombin in order to release a fluorophore, AMC, which can be easily quantified by fluorescence reader at Ex/Em = 350/450 nm. In the presence of Thrombin specific inhibitors, the extent of cleavage reaction is reduced or completely abolished. The loss in the fluorescence intensity can be correlated to the amount of inhibitor present in the assay solution.
The kit provides a simple and rapid method to screen potential inhibitors of thrombin and to characterize thrombin inhibitors found in plasma samples.
This product is manufactured by BioVision, an Abcam company and was previously called K374 Thrombin Inhibitor Screening Kit (Fluorometric). K374-100 is the same size as the 100 test size of ab197007.
Thrombin enzyme (Factor IIa) is an important clotting factor that controls the transformation of soluble fibrinogen to insoluble active fibrin strands. Thrombin is a serine protease (EC 3.4.21.5) that catalyzes many coagulation-related reactions. Thrombin inhibitors are used as anticoagulants to prevent arterial and venous thrombosis. Some of these inhibitors are currently in clinical use while others are in clinical development.
The Safety Datasheet for this product has been updated for certain countries. Please check the current version in the Support and downloads section.
Thrombin also known as Factor II or thrombin protein is a 36 kDa serine protease essential for blood coagulation. It is produced in the liver as prothrombin and activated in the coagulation cascade. Its expression occurs extensively in the liver where it plays an important role in converting soluble fibrinogen into insoluble fibrin forming blood clots. Thrombin also activates various other coagulation factors including Factors V VIII and XI amplifying the coagulation response. Biotinylated thrombin variations help in detection and research applications.
Thrombin modulates several physiological processes beyond clot formation. It serves as a signaling molecule interacting with protease-activated receptors (PARs) to influence cell functions including proliferation migration and apoptosis. Thrombin forms part of the prothrombinase complex comprised of prothrombin activated Factor X (Xa) and Factor V on phospholipid surfaces. This complex is critical for thrombin generation during the clotting cascade. Thrombin's activity extends to involvement in wound healing and inflammation regulation.
Thrombin significantly participates in the coagulation and fibrinolytic pathways. It not only converts fibrinogen to fibrin in the coagulation pathway but also activates inhibitors like antithrombin which regulates thrombin and other protease activities. Thrombin's interaction with fibrinolysis where tPA and plasminogen are substrates integrates clot disintegration processes. Thrombin's connectivity with proteins such as Factor VII Protein C and antithrombin outlines its diverse role in maintaining hemostatic balance.
Thrombin associates with conditions such as venous thromboembolism and disseminated intravascular coagulation (DIC). Dysregulation of thrombin leads to excessive clotting contributing to thromboembolic diseases. In DIC uncontrolled thrombin activity results in systemic coagulation consuming clotting factors and increasing bleeding risk. Its function alongside proteins like Factor V Leiden and antithrombin deficiencies aggravate thrombotic conditions. Research into thrombin inhibitors aids in developing therapeutic strategies for these disorders.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Inhibition of thrombin activity by a thrombin Inhibitor (PPACK Dihydrochloride).
Thrombin activity was measured in plasma samples in the presence and absence of Thrombin Inhibitor (PPACK Dihydrochloride). S = Substrate, I = Inhibitor, AB = Activation Buffer containing Factor Xa. Assays were performed following the kit protocol.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com